TSRI and Receptos (now Celgene) drug poised for further trials against ulcerative colitis, Crohn’s disease and more

RMS is the most common type of multiple sclerosis. Treating inflammation in RMS patients is key to reducing their disease relapses — or “flare ups.” Ozanimod blocks sources of inflammation in RMS by acting as a sphingosine 1-phosphate 1 (S1PR1) receptor agonist.

Read more: https://www.sciencedaily.com/releases/2017/11/171109224027.htm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s